E

Editas Medicine
D

EDIT

1.63000
USD
0.02
(0.93%)
مغلق
حجم التداول
72,193
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
136,446,544
أصول ذات صلة
ALNY
ALNY
3.98
(1.56%)
259.33 USD
B
BEAM
0.400
(2.02%)
20.210 USD
C
CRSP
0.520
(1.38%)
38.220 USD
N
NTLA
0.20000
(2.32%)
8.83000 USD
REGN
REGN
15.98
(2.71%)
606.12 USD
S
SRPT
0.740
(1.18%)
63.550 USD
TMO
TMO
3.67
(0.87%)
423.51 USD
VRTX
VRTX
2.22
(0.45%)
500.92 USD
المزيد
الأخبار المقالات

العنوان: Editas Medicine

القطاع: Healthcare
الصناعة: Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.